We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
101
Martingale Asset Management
Massachusetts
– -$1.48M -38,629 Closed
PA
102
Profund Advisors
Maryland
– -$1.46M -38,127 Closed
GI
103
GAMCO Investors
Connecticut
– -$1.37M -35,650 Closed
Mirae Asset Global Investments
104
Mirae Asset Global Investments
South Korea
– -$1.33M -34,677 Closed
CL
105
CSS LLC
Illinois
– -$1.24M -32,291 Closed
MIM
106
MetLife Investment Management
New Jersey
– -$1.18M -30,585 Closed
AIMCA
107
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$1.15M -30,000 Closed
BCM
108
BCK Capital Management
Connecticut
– -$1.08M -28,107 Closed
AIG
109
American International Group
New York
– -$1.07M -27,923 Closed
Simplex Trading
110
Simplex Trading
Illinois
– -$981K -25,538 Closed
VF
111
Virtu Financial
New York
– -$977K -25,428 Closed
SAM
112
Simplify Asset Management
Nevada
– -$961K -25,000 Closed
Principal Financial Group
113
Principal Financial Group
Iowa
– -$945K -24,599 Closed
UBS AM
114
UBS AM
Illinois
– -$564K -24,360 Closed
Manulife (Manufacturers Life Insurance)
115
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$900K -23,422 Closed
VOYA Investment Management
116
VOYA Investment Management
Georgia
– -$881K -22,939 Closed
Fisher Asset Management
117
Fisher Asset Management
Washington
– -$877K -22,820 Closed
JSW
118
Journey Strategic Wealth
New Jersey
– -$855K -22,257 Closed
MAM
119
Marquette Asset Management
Minnesota
– -$845K -22,000 Closed
ProShare Advisors
120
ProShare Advisors
Maryland
– -$806K -20,973 Closed
EPM
121
Equitec Proprietary Markets
Illinois
– -$772K -20,100 Closed
MCM
122
Moore Capital Management
New York
– -$768K -20,000 Closed
LCM
123
Legato Capital Management
California
– -$767K -19,963 Closed
Janus Henderson Group
124
Janus Henderson Group
United Kingdom
– -$758K -19,736 Closed
NICM
125
Neo Ivy Capital Management
New York
– -$716K -18,648 Closed
3 4
5
6 7

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.